The reveal of a OncoDxRx-invented gene-to-drug prediction technology has sparked a debate across the industry regarding the extent to which it will compete or complement with NGS-based biomarker testing.

PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) is a patient-derived, cfmRNA-based drug response prediction platform, invented and developed by OncoDxRx.

Its development began several years ago, although its capabilities were only disclosed for the first time last year. The system is envisioned to quickly provide personalized drug response results for those cancer patients with progressive disease following therapies (i.e., non-responder population).

According to the company, PGA is designed to have a wide range of predictive power, including drug efficacy, response, residual disease and recurrence risk. Because of its exclusive capabilities, high throughput, low cost and fast turnaround, currently there is no equivalent or anything close in the market today.

“It is clear that the biomarker testing has created a tremendous benchmark you have to meet for entry into a very competitive precision oncology market,” OncoDxRx said. “But if you’re coming in with a revolutionary technology to gap-fill biomarker testing’s limitations, then there is no competition, you actually complete the puzzle, the test menu and benefit more patients.”

The standard-of-care biomarker testing has faced considerable limitations: only qualify 20-30% of patients for precision therapy, costly with at least 2-week turnaround.

As for PGA, OncoDxRx said that while the company sees no competition today, the company nonetheless “welcomes partnership, collaboration to quickly expand the market to benefit more cancer patients.”

The PGA technology stands as a testament to OncoDxRx’s commitment to maintaining a robust and technologically advanced liquid biopsy platform. Its combination of advanced features, including patient-unique gene expression signatures, in silico gene-drug mapping analytics, and drug response prediction capabilities, underscores the company’s dedication to technological flexibility and barrier.

As a key element in OncoDxRx’s pipeline strategy, PGA reflects the ongoing efforts to revolutionize and enhance the exclusiveness of its liquid biopsy arsenal. In an ever-evolving precision oncology landscape, PGA remains a symbol of OncoDxRx’s commitment to safeguarding its interests and contributing to improve patient outcome through a credible and reliable theranostic capability.